drugset / Trial / NCT07267806
Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multi-center randomized phase III clinical study of first-line Camrelizumab and Apatinib with or without intravenous FOLFOX Chemotherapy for Advanced Hepatocellular Carcinoma (HCC).
Timeline
- Start
- 2025-10-31
- Primary completion
- 2029-10
- Completion
- 2032-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | Other |
| Background | Camrelizumab | Monoclonal antibody | 200 mg | Other |
| Background | Rivoceranib | Small molecule | 250 mg | Oral |